Product Code: ETC6192736 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Therapeutic plasma exchange (TPE) in Australia is gaining traction as a treatment for autoimmune and neurological disorders. The process involves removing harmful plasma and replacing it with fresh plasma or a substitute, effectively reducing disease symptoms. The rising prevalence of conditions like multiple sclerosis and Guillain-Barré syndrome is fueling market demand. Advances in plasma separation technologies and supportive healthcare infrastructure are also playing a pivotal role in market growth.
In Australia, therapeutic plasma exchange (TPE) is gaining attention as a treatment for autoimmune and neurological disorders such as Guillain-Barré syndrome and myasthenia gravis. As awareness of TPE`s benefits increases among clinicians, more hospitals are investing in plasmapheresis equipment and trained personnel. The Australian Red Cross Lifeblood`s involvement in plasma collection and distribution ensures a reliable supply chain, which is critical for scaling up TPE services across both public and private hospitals.
In Australia, the therapeutic plasma exchange market is challenged by the limited availability of qualified healthcare professionals and specialized equipment required to perform these procedures. Furthermore, the procedure is expensive and often only accessible in major hospitals, restricting patient access in rural and remote areas. Logistical constraints related to plasma storage and supply also add to the operational difficulties. The invasive nature of the procedure and lack of public awareness further limit market penetration.
The therapeutic plasma exchange (TPE) segment in Australia offers niche yet high-potential investment opportunities, especially for specialized device manufacturers and clinical service providers. With a growing focus on autoimmune and neurological treatments, private investors can support the expansion of plasma treatment centers or invest in improved apheresis equipment. Strategic collaborations with pathology labs, hospitals, and mobile blood service providers like Lifeblood offer scalable business models. Investors can also consider funding research into next-gen filtration technologies for TPE.
Policies governing therapeutic plasma exchange in Australia are largely tied to the regulation of blood and plasma products, overseen by the National Blood Authority (NBA). While the NBA ensures a safe and steady supply of blood components, policies are conservative in expanding the scope of therapeutic plasma exchange as a standard treatment. This cautious approach restricts the number of eligible treatment centers and patient access, especially in regional areas. Moreover, reimbursement pathways for plasma exchange remain unclear in many cases, limiting private sector participation.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Therapeutic Plasma Exchange Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Therapeutic Plasma Exchange Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Therapeutic Plasma Exchange Market - Industry Life Cycle |
3.4 Australia Therapeutic Plasma Exchange Market - Porter's Five Forces |
3.5 Australia Therapeutic Plasma Exchange Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Australia Therapeutic Plasma Exchange Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Australia Therapeutic Plasma Exchange Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Therapeutic Plasma Exchange Market Trends |
6 Australia Therapeutic Plasma Exchange Market, By Types |
6.1 Australia Therapeutic Plasma Exchange Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Neurological Disorders, 2021- 2031F |
6.1.4 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Renal Disorders, 2021- 2031F |
6.1.5 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Hematology Disorders, 2021- 2031F |
6.1.6 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Metabolic Disorders, 2021- 2031F |
6.2 Australia Therapeutic Plasma Exchange Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.2.3 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.2.4 Australia Therapeutic Plasma Exchange Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
7 Australia Therapeutic Plasma Exchange Market Import-Export Trade Statistics |
7.1 Australia Therapeutic Plasma Exchange Market Export to Major Countries |
7.2 Australia Therapeutic Plasma Exchange Market Imports from Major Countries |
8 Australia Therapeutic Plasma Exchange Market Key Performance Indicators |
9 Australia Therapeutic Plasma Exchange Market - Opportunity Assessment |
9.1 Australia Therapeutic Plasma Exchange Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Australia Therapeutic Plasma Exchange Market Opportunity Assessment, By Application, 2021 & 2031F |
10 Australia Therapeutic Plasma Exchange Market - Competitive Landscape |
10.1 Australia Therapeutic Plasma Exchange Market Revenue Share, By Companies, 2024 |
10.2 Australia Therapeutic Plasma Exchange Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |